# Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

> **NCT07098988** · PHASE2 · RECRUITING · sponsor: **CatalYm GmbH** · enrollment: 107 (estimated)

## Conditions studied

- Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Adult Solid Tumor

## Interventions

- **BIOLOGICAL:** Visugromab
- **DRUG:** Matching placebo for visugromab
- **BIOLOGICAL:** Pembrolizumab 200 mg Q3W
- **DRUG:** Pemetrexed 500 mg/m^2
- **DRUG:** Carboplatin AUC 5

## Key facts

- **NCT ID:** NCT07098988
- **Lead sponsor:** CatalYm GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2029-03-31
- **Final completion:** 2031-03-31
- **Target enrollment:** 107 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07098988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07098988, "Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07098988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*